The Association of Sarcopenia and Visceral Obesity with Lean Nonalcoholic Fatty Liver Disease in Chinese Patients with Type 2 Diabetes Mellitus

作者：Xingxing Zhang, Zhiying He, Qiya Si, Xiang Hu, Lijuan Yang, Xiao Gu, Lin-Jia Du, Lei Wang, Le‐Lin Pan, Yingqian Li, Jing Li, Bo Yang, Xuejiang Gu · 发表于：Journal of Diabetes Research · 年份：2022 · DOI：10.1155/2022/2229139 · 被引用次数：25 · 研究领域：Nutrition and Health in Aging、Liver Disease Diagnosis and Treatment、Body Composition Measurement Techniques

Background. Few studies have specifically observed the relationship of sarcopenia, visceral obesity, or their joint effects with lean NAFLD in patients with diabetes. We aimed to investigate the associations of lean NAFLD with sarcopenia, visceral obesity, and sarcopenic visceral obesity (SV) in Chinese patients with type 2 diabetes mellitus (T2DM). Methods. Altogether, 1,112 T2DM patients with BMI <25 kg/m2 were enrolled, and 33.18% of them were diagnosed with lean NAFLD by abdominal ultrasonography. Body composition markers were measured by bioelectrical impedance (BIA). Skeletal muscle mass index (SMI) was calculated as appendicular skeletal muscle mass (ASM) divided by weight, and sarcopenia was defined as SMI < 1 standard deviation SD below the sex-specific average for a young reference population. Visceral obesity was defined as visceral fat area VFA ≥ 100 c m 2 . Participants were categorized into one of the four body composition groups: nonsarcopenia/nonvisceral obesity (NN), nonsarcopenia/visceral obesity (NV), sarcopenia/nonvisceral obesity (SN), and SV. Results. Compared to those in the NN group, patients in the NV and SN groups had a higher risk of lean NAFLD after full adjustments (NV: OR = 1.74 ; 95% CI: 1.09, 2.78; SN: OR =2.07; 95% CI: 1.23, 3.46). Of note, patients in the SV group had the highest odds of lean NAFLD ( OR = 3.29 ; 95% CI: 2.10, 5.17). There wer...